A scale cannot distinguish fat, muscle and water. Studies of muscle loss during GLP-1 treatment often report lean mass measured by a body composition scan. Lean mass includes muscle, water and organs. The scan does not measure strength.
What the review measured
A systematic review pooled 20 randomized trials with 15,782 participants [1]. Lean mass accounted for 35.2% of weight lost in semaglutide groups, 26.8% in liraglutide groups and 25.4% in tirzepatide groups. Study results varied substantially. The drug estimates came from separate studies, so the numbers cannot rank the drugs for retaining muscle.
Lifestyle intervention alone yielded a pooled estimate of 26.2%. The difference between the pooled medication and lifestyle estimates did not reach statistical significance (p = 0.42). A higher share of a smaller weight loss can still represent fewer pounds of lean tissue.
What the tirzepatide trial measured directly
A SURMOUNT-1 substudy used body composition scans from 160 participants at baseline and week 72 [2]. Fat comprised 74% of weight lost with tirzepatide and 75% with placebo. Lean mass accounted for 26% and 25%, respectively. The tirzepatide group lost more total weight.
Where strength training and nutrition fit
The pooled lean share was 17.5% in trials that combined lifestyle changes with resistance training [1]. Questions about protein intake during GLP-1 treatment also arise when your appetite drops. The review cannot predict how much lean tissue any one person will retain with exercise or dietary changes.